This document summarizes an agenda for a meeting to discuss a challenge focused on developing a mobile application to help underserved and minority women prevent and fight breast and gynecologic cancers. The agenda includes introductions, an overview of the challenge, and a Q&A session. The challenge calls for an application that provides information on preventive services, allows interface with patient health records, supports care plans and remote follow-up, and supports patient engagement and caregiving. Disparities in cancer rates among racial and ethnic groups are also discussed.
What Black Women Need to Know About Endometrial Cancerbkling
Dr. Kemi Doll, gynecologic oncologist at the University of Washington Medical Center, shares her passion for improving the lives of black women affected by this disease through her extensive research and knowledge about endometrial cancer.
This webinar is being put on in partnership with ECANA.
1) The document discusses whether oncologists should routinely discuss fertility preservation options with cancer patients of childbearing age.
2) It reviews guidelines published in 2006 by the American Society of Clinical Oncology recommending that oncologists address potential treatment-induced infertility.
3) However, several national surveys since 2006 found that oncologists are still not routinely discussing fertility risks or referring patients to specialists.
Uterine and endometrial cancer are the most common gynecologic cancers. Risk factors include obesity, tamoxifen use, and certain genetic conditions. Diagnosis involves endometrial biopsy. Treatment typically involves hysterectomy with or without radiation or chemotherapy depending on risk factors like tumor grade and stage. New immunotherapies are showing promise for recurrent or advanced disease. Precision medicine approaches are helping to classify subtypes and identify targeted therapies.
The document summarizes information about male breast cancer. Some key points:
1) Male breast cancer is considered a rare or "orphan" disease that affects about 1 in 1000 men annually in the US, with estimated new cases of 2,140 and deaths of 450 in 2011.
2) The causes of male breast cancer include gene mutations like BRCA2 and PTEN, as well as factors like estrogen exposure.
3) Male breast cancer has some similarities to female breast cancer, especially the luminal/hormone receptor positive subtype, but the incidence peaks about 10 years later in men at age 75 compared to age 61 in women.
4) Treatment options are generally the same as for
This document discusses expanding access to cancer care and control in low and middle income countries. It summarizes that cancer is a leading cause of death globally and the burden is disproportionately affecting the poor. However, many cancers are preventable or treatable. The document outlines Mexico's approach of integrating cancer services into its universal health coverage program to improve access and outcomes for diseases like breast and cervical cancer.
This study examined 114 pregnancies in 54 women with non-gynecologic cancer at a hospital in Saudi Arabia between 1990-2001. The study divided the pregnancies into two groups: Group I included 18 pregnancies where cancer was active during pregnancy, and Group II included 96 pregnancies where cancer was in remission during pregnancy. The study found that live birth rates were 66.7% for Group I and 87.5% for Group II, with a statistically significant difference between the groups. It also found 3 maternal deaths in Group I but no deaths in Group II. The most common cancers were thyroid and breast cancer. The study concluded that active cancer during pregnancy carries higher risks of adverse maternal and fetal outcomes compared to pregnancy
1) Romania has high rates of cervical cancer mortality compared to other European countries due to undervaluation of preventive care like Pap smears.
2) A study found that only 20% of Romanian women have ever had a Pap smear, with many lacking awareness or believing smears are unnecessary.
3) Barriers to screening included costs, fear of diagnosis, and perceptions that doctors are overburdened. The health system is underfunded and screening program exists only on paper.
Deborah Collyar, President, Patient Advocates In Research, discusses what new research is telling us about DCIS, both here and abroad. What is low risk DCIS? Is it okay to monitor your DCIS? Is Endocrine Therapy absolutely necessary? What does the future look like? Deborah addresses this and so much more.
What Black Women Need to Know About Endometrial Cancerbkling
Dr. Kemi Doll, gynecologic oncologist at the University of Washington Medical Center, shares her passion for improving the lives of black women affected by this disease through her extensive research and knowledge about endometrial cancer.
This webinar is being put on in partnership with ECANA.
1) The document discusses whether oncologists should routinely discuss fertility preservation options with cancer patients of childbearing age.
2) It reviews guidelines published in 2006 by the American Society of Clinical Oncology recommending that oncologists address potential treatment-induced infertility.
3) However, several national surveys since 2006 found that oncologists are still not routinely discussing fertility risks or referring patients to specialists.
Uterine and endometrial cancer are the most common gynecologic cancers. Risk factors include obesity, tamoxifen use, and certain genetic conditions. Diagnosis involves endometrial biopsy. Treatment typically involves hysterectomy with or without radiation or chemotherapy depending on risk factors like tumor grade and stage. New immunotherapies are showing promise for recurrent or advanced disease. Precision medicine approaches are helping to classify subtypes and identify targeted therapies.
The document summarizes information about male breast cancer. Some key points:
1) Male breast cancer is considered a rare or "orphan" disease that affects about 1 in 1000 men annually in the US, with estimated new cases of 2,140 and deaths of 450 in 2011.
2) The causes of male breast cancer include gene mutations like BRCA2 and PTEN, as well as factors like estrogen exposure.
3) Male breast cancer has some similarities to female breast cancer, especially the luminal/hormone receptor positive subtype, but the incidence peaks about 10 years later in men at age 75 compared to age 61 in women.
4) Treatment options are generally the same as for
This document discusses expanding access to cancer care and control in low and middle income countries. It summarizes that cancer is a leading cause of death globally and the burden is disproportionately affecting the poor. However, many cancers are preventable or treatable. The document outlines Mexico's approach of integrating cancer services into its universal health coverage program to improve access and outcomes for diseases like breast and cervical cancer.
This study examined 114 pregnancies in 54 women with non-gynecologic cancer at a hospital in Saudi Arabia between 1990-2001. The study divided the pregnancies into two groups: Group I included 18 pregnancies where cancer was active during pregnancy, and Group II included 96 pregnancies where cancer was in remission during pregnancy. The study found that live birth rates were 66.7% for Group I and 87.5% for Group II, with a statistically significant difference between the groups. It also found 3 maternal deaths in Group I but no deaths in Group II. The most common cancers were thyroid and breast cancer. The study concluded that active cancer during pregnancy carries higher risks of adverse maternal and fetal outcomes compared to pregnancy
1) Romania has high rates of cervical cancer mortality compared to other European countries due to undervaluation of preventive care like Pap smears.
2) A study found that only 20% of Romanian women have ever had a Pap smear, with many lacking awareness or believing smears are unnecessary.
3) Barriers to screening included costs, fear of diagnosis, and perceptions that doctors are overburdened. The health system is underfunded and screening program exists only on paper.
Deborah Collyar, President, Patient Advocates In Research, discusses what new research is telling us about DCIS, both here and abroad. What is low risk DCIS? Is it okay to monitor your DCIS? Is Endocrine Therapy absolutely necessary? What does the future look like? Deborah addresses this and so much more.
This document discusses expanding access to cancer care and control in low and middle income countries. It argues that expanding access should, could, and can be done. Cancer disproportionately impacts the poor due to greater exposure to risk factors and less access to prevention and treatment. Integrating cancer services into existing health programs through "diagonal" approaches can help address this inequity while strengthening overall health systems. Examples from Mexico integrating breast and cervical cancer screening into primary care and social programs show progress, but more opportunities remain to improve early detection and survival rates.
This study aimed to predict the risk of malignancy in women with adnexal masses using preoperative factors. The researchers analyzed 395 patients and found:
1) Tumor morphology on ultrasound, elevated serum CA 125 levels, presence of ascites, and older age were associated with higher risk of malignancy.
2) Patients with solid or complex masses and CA 125 > 35 U/mL had a positive predictive value of 84.7% for malignancy.
3) Purely cystic masses had a 100% negative predictive value for ruling out malignancy.
4) The combination of complex/solid mass and elevated CA 125 best defined patients at high risk of ovarian cancer.
Chile has a population of over 16 million people with 85% living in urban areas. The public health insurance system covers 70.4% of the population while private insurance covers 15.3%. Cancer is the second leading cause of death in Chile, with an estimated 24,000 new cases per year and 400-480 cases in children under 15 years old. The public health system operates 42 breast pathology units and 43 cervical pathology units along with cancer treatment centers and palliative care units to address cancer. Key challenges include improving early detection, making interventions more cost-effective and affordable, and improving personalized cancer treatments through collaborative research.
Critical Remarks to Endoscopic Surgery for Endometrial Cancer and Sarcoma, Ce...CrimsonpublishersCancer
The document discusses critical issues with endoscopic surgery for gynecological cancers. It summarizes the development of endoscopic surgery for cancers and highlights concerns. For endometrial cancer and sarcoma, it notes the risks of morcellation potentially spreading tissue. It also discusses the challenges of diagnosing leiomyosarcoma preoperatively. For cervical cancer, it outlines the history of surgical approaches and recent randomized trials showing lower survival rates with minimally invasive versus open radical hysterectomies, calling into question the equivalency of cancer outcomes between the two approaches.
Women in Mexico, Colombia, Ecuador, and Peru chose medical abortion to avoid a more invasive surgical procedure. They viewed medical abortion as less painful and risky than surgery. Cost was also a factor, as medical abortion was generally less expensive than surgical abortion. While some women had negative experiences with pain or bleeding, most found the method acceptable. Psychosocial support was important, especially for vulnerable groups.
Black women experience higher rates of breast cancer and mortality compared to other groups in the US. Some factors that may contribute include less access to screening and treatment, as well as a higher frequency of more aggressive tumor subtypes like triple negative breast cancer. Research has found Black women are also more likely to be diagnosed with breast cancers that have exhausted immune cells surrounding the tumor. Factors like ancestry, a stronger pro-inflammatory response, lower breastfeeding rates, and lower vitamin D levels may all play a role in the increased aggressiveness seen in Black women's breast cancers. Ongoing research aims to better understand and address these disparities.
Burden of Cervical Cancer & other HPV Related Diseases : Indian Perspectiv...Lifecare Centre
HPV RELATED DISEASES
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer. HPV causes virtually 100% of cervical cancer cases
There is growing evidence of HPV being a relevant factor in other ANOGENITAL CANCERS (anus, vulva, vagina and penis) and head and neck cancers.
HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts
Uterine Cancer Recurrence: All You Need To Knowbkling
t's not uncommon for uterine cancer survivors to worry about recurrence.
Whether you've had a recurrence or want to become more informed, join Dr. Susan C. Modesitt, Director of Gynecologic Oncology at UVA Cancer Center, to learn more information about uterine cancer recurrence as well as available treatment options.
All in the Family: Hereditary Risk for Gynecologic Cancerbkling
Knowing and understanding your inherited genetics is important for ovarian and uterine cancer patients. Dr. Melissa Frey, gynecologic oncologist at Weill Cornell Medicine, discusses how genetic factors affect women with ovarian and uterine cancer and influence treatment decisions, with a particular focus on BRCA1 & 2 and Lynch Syndrome.
This webinar was being put on in partnership with FORCE.
Dr. Jennifer Mueller, gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center, will share research updates on uterine/endometrial cancer and other new developments in treatment and surgery.
The role of Hysterectomy on BRCA mutation carriersValentina Cará
Hysterectomy may reduce the risk of uterine cancer for BRCA mutation carriers taking tamoxifen, by allowing estrogen-only hormone therapy and eliminating the uterine cancer risk from tamoxifen. However, the risks of hysterectomy, such as surgical complications, need to be weighed against the uncertain increased uterine cancer risk from tamoxifen. Studies have found both increased and similar uterine cancer rates in BRCA carriers taking tamoxifen compared to the general population. The decision to perform hysterectomy should be individualized based on risk factors and treatment options.
This document discusses expanding access to cancer care and control in low and middle income countries. It begins with Felicia Knaul's background and experience with cancer advocacy. It then discusses the growing cancer burden in LMICs, including increasing rates of breast and cervical cancer. It challenges myths about cancer being unnecessary, unaffordable, and impossible to treat in LMICs. It argues that investing in cancer care in LMICs is cost effective and many treatments are affordable. It discusses strategies like integrating cancer services into existing health programs and financing mechanisms to expand access in an affordable way. It highlights examples from Mexico where universal health insurance has expanded coverage of cancer treatment. In summary, it makes the case that much can and should
This document provides an overview of breast cancer, including epidemiology, etiology, risk factors, screening and prevention, diagnosis, and treatment. Some key points include:
- Breast cancer is the most common malignancy in women and a heterogeneous disease at the molecular level.
- Risk factors include gender, age, family history, benign breast disease, and hormonal or reproductive factors.
- Screening methods include breast self-exam, clinical exam, mammography, and MRI. Screening recommendations depend on risk level.
- Diagnosis involves determining hormone receptor and HER2 status. Molecular subtypes include luminal A/B, HER2-positive, and triple negative.
- Treatment involves surgery, radiation
Report Back from SGO: What’s the Latest in Uterine Cancer?bkling
Dr. Jeannine Villella, Chief of Gynecologic Oncology at Lenox Hill Hospital, provides a comprehensive update from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Dr. Villella breaks down what the research presented at the conference means for you and discusses new developments.
1) The study assessed the impact of transitioning from film to digital mammography for breast cancer screening through the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which provides mammograms to low-income, uninsured women.
2) Using microsimulation models, the study predicted digital mammography would result in slightly more life-years gained than film, but with higher costs.
3) Assuming a fixed budget, the transition to digital would result in fewer women screened and fewer life-years gained due to the higher costs of digital mammography. Changing to biennial digital screening could increase life-years gained compared to annual screening with a fixed budget.
Navigating Nutrition During Cancer and COVID-19bkling
Nutrition can be puzzling enough, but when you add a cancer diagnosis and a global pandemic, it’s even harder to make sense of it all. Julie Lanford, MPH, RD, CSO, LDN, "The Cancer Dietitian" for Cancer Services, will help put the pieces together so you’re equipped to navigate nutrition during cancer and COVID-19.
This document describes a breast cancer screening technology called the Mammary Aspirate Specimen Cytology Test (MASCT) developed by Atossa Genetics. The MASCT uses a reusable device to non-invasively collect nipple aspirate fluid, which contains cells that can be analyzed to detect pre-cancerous changes up to 8 years before mammography. The company plans to launch the MASCT product and an accompanying cytology analysis service in breast clinics across the US to tap into the $13 billion annual breast cancer screening market. Management aims to improve the technology and expand the types of molecular biomarkers analyzed over time to further advance breast cancer risk assessment.
Breast cancer screening is well established in Israel through a national screening program. Jewish Israeli women have a higher incidence of breast cancer at a younger age than Arab women or those in neighboring countries, likely due to high rates of BRCA mutations. The screening program has high compliance rates, detects over 30% of new breast cancer cases annually at early stages, and works to increase screening in remote and ultra-orthodox communities through education and mobile units. Analysis of screening results helps adjust the program over time.
The webinar provided information on the Active Schools Acceleration Project (ASAP) Innovation Competition. The competition has two categories - School Programs and Technology Innovation. It seeks innovative physical activity programs and technologies to increase activity in schools. Regional and national winners will receive cash awards and the opportunity to participate in pilot programs to expand their initiatives.
This document discusses expanding access to cancer care and control in low and middle income countries. It argues that expanding access should, could, and can be done. Cancer disproportionately impacts the poor due to greater exposure to risk factors and less access to prevention and treatment. Integrating cancer services into existing health programs through "diagonal" approaches can help address this inequity while strengthening overall health systems. Examples from Mexico integrating breast and cervical cancer screening into primary care and social programs show progress, but more opportunities remain to improve early detection and survival rates.
This study aimed to predict the risk of malignancy in women with adnexal masses using preoperative factors. The researchers analyzed 395 patients and found:
1) Tumor morphology on ultrasound, elevated serum CA 125 levels, presence of ascites, and older age were associated with higher risk of malignancy.
2) Patients with solid or complex masses and CA 125 > 35 U/mL had a positive predictive value of 84.7% for malignancy.
3) Purely cystic masses had a 100% negative predictive value for ruling out malignancy.
4) The combination of complex/solid mass and elevated CA 125 best defined patients at high risk of ovarian cancer.
Chile has a population of over 16 million people with 85% living in urban areas. The public health insurance system covers 70.4% of the population while private insurance covers 15.3%. Cancer is the second leading cause of death in Chile, with an estimated 24,000 new cases per year and 400-480 cases in children under 15 years old. The public health system operates 42 breast pathology units and 43 cervical pathology units along with cancer treatment centers and palliative care units to address cancer. Key challenges include improving early detection, making interventions more cost-effective and affordable, and improving personalized cancer treatments through collaborative research.
Critical Remarks to Endoscopic Surgery for Endometrial Cancer and Sarcoma, Ce...CrimsonpublishersCancer
The document discusses critical issues with endoscopic surgery for gynecological cancers. It summarizes the development of endoscopic surgery for cancers and highlights concerns. For endometrial cancer and sarcoma, it notes the risks of morcellation potentially spreading tissue. It also discusses the challenges of diagnosing leiomyosarcoma preoperatively. For cervical cancer, it outlines the history of surgical approaches and recent randomized trials showing lower survival rates with minimally invasive versus open radical hysterectomies, calling into question the equivalency of cancer outcomes between the two approaches.
Women in Mexico, Colombia, Ecuador, and Peru chose medical abortion to avoid a more invasive surgical procedure. They viewed medical abortion as less painful and risky than surgery. Cost was also a factor, as medical abortion was generally less expensive than surgical abortion. While some women had negative experiences with pain or bleeding, most found the method acceptable. Psychosocial support was important, especially for vulnerable groups.
Black women experience higher rates of breast cancer and mortality compared to other groups in the US. Some factors that may contribute include less access to screening and treatment, as well as a higher frequency of more aggressive tumor subtypes like triple negative breast cancer. Research has found Black women are also more likely to be diagnosed with breast cancers that have exhausted immune cells surrounding the tumor. Factors like ancestry, a stronger pro-inflammatory response, lower breastfeeding rates, and lower vitamin D levels may all play a role in the increased aggressiveness seen in Black women's breast cancers. Ongoing research aims to better understand and address these disparities.
Burden of Cervical Cancer & other HPV Related Diseases : Indian Perspectiv...Lifecare Centre
HPV RELATED DISEASES
Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer. HPV causes virtually 100% of cervical cancer cases
There is growing evidence of HPV being a relevant factor in other ANOGENITAL CANCERS (anus, vulva, vagina and penis) and head and neck cancers.
HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts
Uterine Cancer Recurrence: All You Need To Knowbkling
t's not uncommon for uterine cancer survivors to worry about recurrence.
Whether you've had a recurrence or want to become more informed, join Dr. Susan C. Modesitt, Director of Gynecologic Oncology at UVA Cancer Center, to learn more information about uterine cancer recurrence as well as available treatment options.
All in the Family: Hereditary Risk for Gynecologic Cancerbkling
Knowing and understanding your inherited genetics is important for ovarian and uterine cancer patients. Dr. Melissa Frey, gynecologic oncologist at Weill Cornell Medicine, discusses how genetic factors affect women with ovarian and uterine cancer and influence treatment decisions, with a particular focus on BRCA1 & 2 and Lynch Syndrome.
This webinar was being put on in partnership with FORCE.
Dr. Jennifer Mueller, gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center, will share research updates on uterine/endometrial cancer and other new developments in treatment and surgery.
The role of Hysterectomy on BRCA mutation carriersValentina Cará
Hysterectomy may reduce the risk of uterine cancer for BRCA mutation carriers taking tamoxifen, by allowing estrogen-only hormone therapy and eliminating the uterine cancer risk from tamoxifen. However, the risks of hysterectomy, such as surgical complications, need to be weighed against the uncertain increased uterine cancer risk from tamoxifen. Studies have found both increased and similar uterine cancer rates in BRCA carriers taking tamoxifen compared to the general population. The decision to perform hysterectomy should be individualized based on risk factors and treatment options.
This document discusses expanding access to cancer care and control in low and middle income countries. It begins with Felicia Knaul's background and experience with cancer advocacy. It then discusses the growing cancer burden in LMICs, including increasing rates of breast and cervical cancer. It challenges myths about cancer being unnecessary, unaffordable, and impossible to treat in LMICs. It argues that investing in cancer care in LMICs is cost effective and many treatments are affordable. It discusses strategies like integrating cancer services into existing health programs and financing mechanisms to expand access in an affordable way. It highlights examples from Mexico where universal health insurance has expanded coverage of cancer treatment. In summary, it makes the case that much can and should
This document provides an overview of breast cancer, including epidemiology, etiology, risk factors, screening and prevention, diagnosis, and treatment. Some key points include:
- Breast cancer is the most common malignancy in women and a heterogeneous disease at the molecular level.
- Risk factors include gender, age, family history, benign breast disease, and hormonal or reproductive factors.
- Screening methods include breast self-exam, clinical exam, mammography, and MRI. Screening recommendations depend on risk level.
- Diagnosis involves determining hormone receptor and HER2 status. Molecular subtypes include luminal A/B, HER2-positive, and triple negative.
- Treatment involves surgery, radiation
Report Back from SGO: What’s the Latest in Uterine Cancer?bkling
Dr. Jeannine Villella, Chief of Gynecologic Oncology at Lenox Hill Hospital, provides a comprehensive update from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Dr. Villella breaks down what the research presented at the conference means for you and discusses new developments.
1) The study assessed the impact of transitioning from film to digital mammography for breast cancer screening through the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which provides mammograms to low-income, uninsured women.
2) Using microsimulation models, the study predicted digital mammography would result in slightly more life-years gained than film, but with higher costs.
3) Assuming a fixed budget, the transition to digital would result in fewer women screened and fewer life-years gained due to the higher costs of digital mammography. Changing to biennial digital screening could increase life-years gained compared to annual screening with a fixed budget.
Navigating Nutrition During Cancer and COVID-19bkling
Nutrition can be puzzling enough, but when you add a cancer diagnosis and a global pandemic, it’s even harder to make sense of it all. Julie Lanford, MPH, RD, CSO, LDN, "The Cancer Dietitian" for Cancer Services, will help put the pieces together so you’re equipped to navigate nutrition during cancer and COVID-19.
This document describes a breast cancer screening technology called the Mammary Aspirate Specimen Cytology Test (MASCT) developed by Atossa Genetics. The MASCT uses a reusable device to non-invasively collect nipple aspirate fluid, which contains cells that can be analyzed to detect pre-cancerous changes up to 8 years before mammography. The company plans to launch the MASCT product and an accompanying cytology analysis service in breast clinics across the US to tap into the $13 billion annual breast cancer screening market. Management aims to improve the technology and expand the types of molecular biomarkers analyzed over time to further advance breast cancer risk assessment.
Breast cancer screening is well established in Israel through a national screening program. Jewish Israeli women have a higher incidence of breast cancer at a younger age than Arab women or those in neighboring countries, likely due to high rates of BRCA mutations. The screening program has high compliance rates, detects over 30% of new breast cancer cases annually at early stages, and works to increase screening in remote and ultra-orthodox communities through education and mobile units. Analysis of screening results helps adjust the program over time.
The webinar provided information on the Active Schools Acceleration Project (ASAP) Innovation Competition. The competition has two categories - School Programs and Technology Innovation. It seeks innovative physical activity programs and technologies to increase activity in schools. Regional and national winners will receive cash awards and the opportunity to participate in pilot programs to expand their initiatives.
This document provides an overview and agenda for a webinar about the Palo Alto Medical Foundation's linkAges Developer Challenge and Accelerator Project. The challenge focuses on developing solutions for "signal detection" to identify physical and social health risks for seniors. The webinar agenda includes introductions, an overview of the challenge and program, and a Q&A. It outlines the kick-off event in April, 3-month developer challenge, evaluation criteria, prizes, and timeline for the accelerator program.
Allscripts Open App Challenge Phase 1 Submission Templatehealth2dev
The document describes a solution that addresses healthcare problems by improving management of chronic diseases or value-based care. It is at the prototype or code development stage. The solution will integrate with Allscripts solutions and be brought to market targeting Allscripts customer segments. A video demonstration shows how the solution improves outcomes for healthcare providers or patients. Reasons are provided for selecting this solution.
MCR Global provides an innovative mobile health technology solution that allows for the interoperable, remote transmission of vital health data anywhere, anytime, to anyone during a personal medical emergency or disaster event. The solution displays data through multiple methods including a private web platform, QR technology on smartphones, a universal web app, SMS, or live operators. It notifies emergency contacts and transmits patient health information to emergency rooms prior to arrival. The solution addresses the healthcare problem of not having vital health data accessible at the point of care, which can avoid adverse events.
Health 2.0 Berlin Code-a-Thon - Sponsored By Aetna Internationalhealth2dev
The document summarizes Aetna International's mobile strategy and current capabilities. The strategy focuses first on providing member self-service tools via mobile apps, second on improving member health through condition management apps, and third on tools to expand their customer base. Currently, Aetna International has a mobile optimized website in multiple languages and provider directory apps for iOS and Android in several regions. They also have a marketing iPad app for brokers.
This document summarizes a webinar for the Novartis Thalassemia App Challenge. It introduces the challenge to develop a smartphone app to help thalassemia patients better manage their disease. The challenge will have two phases: the first involves submitting a concept and the second involves developing and demoing an app prototype. A total of $125,000 in prizes will be awarded based on creativity, design, ability to drive patient engagement, and partnership potential with Novartis. The deadline for phase one is June 30th and phase two submissions are due September 8th.
Reducing Cancer Challenge Webinar Deck (12/6/12)health2dev
This document summarizes a webinar discussing efforts to reduce cancer among women of color. It provides background on breast and gynecological cancers rates and disparities among racial and ethnic groups. The webinar focused on a challenge to develop a mobile application to provide underserved and minority women with information on cancer prevention, screening, and treatment options in multiple languages. The application would allow interface with patient health records to provide reminders and support regarding preventive services timing.
The document summarizes an Apps4Tots Health Challenge webinar that provided information about integrating the TXT4Tots message library into new or existing platforms using the HealthData.gov API. It describes the goals of promoting innovation and highlighting excellence in health IT. Details are provided about accessing the API, example requests and response fields. The challenge calls for creative applications that enhance existing platforms or services by integrating the message content. Criteria for applications include usability, completeness, creativity, and innovative integration into a larger platform. A timeline and prizes for the competition are also outlined.
This document discusses health promotion activities and resources for African American women with breast cancer. It outlines various programs and efforts aimed at different levels of prevention - primary, secondary, and tertiary. Primary prevention focuses on education and awareness, secondary on screenings and early detection, and tertiary on treatment and clinical research. While some programs have helped increase mammography rates and diagnoses of early-stage cancers, barriers still exist. Ongoing efforts are needed to ensure all women have access to quality care across the breast cancer continuum.
When reducing cancer risk in our population, let’s not exacerbate disparitiesGraham Colditz
The document discusses reducing cancer disparities through precision prevention approaches. It highlights that while precision medicine focuses on treating existing disease, precision prevention aims to tailor behavioral interventions to individual characteristics to reduce cancer risk. However, efforts to refine prevention strategies could inadvertently worsen disparities if factors like health literacy levels and access to care are not considered. Priorities for avoiding disparities include collaborating with diverse partners to improve communication and applying implementation research approaches to ensure evidence-based programs reach all groups.
This document discusses disparities in heart disease among women of different ethnicities. It summarizes that Native American, Hispanic, and African American women have higher rates of heart disease mortality compared to Asian American and white women. It then discusses various risk factors for heart disease like high cholesterol, diabetes, obesity rates, exercise levels, and smoking rates among different ethnic groups of women. It also addresses biases in referral to certain cardiac procedures and treatments among African American patients.
This document presents health disparity data for African American women in Los Angeles County across several metrics. It shows that African Americans have higher rates of poverty, lower life expectancy, higher rates of obesity, hypertension, and infant mortality compared to other racial/ethnic groups in the county. Data on potential years of life lost and causes of mortality also demonstrate greater health burdens for African Americans.
Why are Breast Cancers More Aggressive in Black Women?bkling
There are striking disparities in survival rates between Black and white breast cancer patients. Our guest speakers, Christine Ambrosone, PhD, and Song Yao, MD, PhD, have led a team that has done extensive research to understand the causes of why certain cancers are more aggressive in Black women. They have developed a hypothesis that the higher rate of aggressive tumors in Black women when compared with white women might have something to do with their immune systems. We will get updates from their research and how we can work towards eliminating racial gaps in breast cancer survival.
1. Collective statistical illiteracy in healthcare is widespread among physicians, patients, and politicians due to non-transparent framing of information and lack of risk communication training.
2. Studies show physicians and the public poorly understand concepts like survival rates, risk reductions, and probabilities related to cancer screenings.
3. Implementing transparent risk communication frameworks in medical education and public health materials is needed to improve informed decision making.
The document discusses breast cancer screening guidelines and recommendations. It notes that various medical organizations have different guidelines for mammography screening, with some recommending annual screening beginning at age 40 while others recommend biennial screening between ages 50-74. The document also discusses debates around overdiagnosis from mammography screening and challenges in assessing its effectiveness due to the slow progression of breast cancer.
26th International Papillomavirus Conference: Satellite Symposium
Enhancing HPV Prevention among Indigenous Populations: International Perspectives on Health and Well-Being
Montreal, Quebec
July 5, 2010
Panel 2: Primary and Secondary Prevention of HPV Diseases, Cervical and other cancers among Indigenous Populations: Promising Interventions and Wise Practices.
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
You’ve been treated for uterine cancer. Now what? With surveillance strategies varying from doctor to doctor, it can be hard to know which advice you should follow. Dr. Jennifer Mueller, Head of the Endometrial Cancer Section, Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, delves into surveillance guidelines, which tests to consider, and how to keep an eye out for any symptoms which could indicate recurrence.
Sharad Ghamande, MD, FACOG
Professor and Director of Gynecologic Oncology
Augusta University Cancer Center
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Wendy Noe, education coordinator for the Central Indiana Affiliate of Susan G. Komen for the Cure® presents an overview of breast cancer information, facts and advances in treatment.
Annual Report to the Nation on the Status of Cancer,Part I .docxjack60216
Annual Report to the Nation on the Status of Cancer,
Part I: National Cancer Statistics
Kathleen A. Cronin, PhD, MPH1; Andrew J. Lake, BS2; Susan Scott, MPH 1; Recinda L. Sherman, MPH, PhD, CTR3;
Anne-Michelle Noone, MS1; Nadia Howlader, MS, PhD1; S. Jane Henley, MSPH4; Robert N. Anderson, PhD5;
Albert U. Firth, BS2; Jiemin Ma, PhD, MHS6; Betsy A. Kohler, MPH, CTR3; and Ahmedin Jemal, DVM, PhD 6
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates
on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-
funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the
National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all can-
cers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the
annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rec-
tum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. RESULTS: Overall cancer incidence rates from 2008 to
2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015
decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-
year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18
most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14
of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal
(men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and
women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men
only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial
and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other
racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men
and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from
2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV)
for colorectal cancer, from 55.
Annual Report to the Nation on the Status of Cancer,Part I .docxrossskuddershamus
Annual Report to the Nation on the Status of Cancer,
Part I: National Cancer Statistics
Kathleen A. Cronin, PhD, MPH1; Andrew J. Lake, BS2; Susan Scott, MPH 1; Recinda L. Sherman, MPH, PhD, CTR3;
Anne-Michelle Noone, MS1; Nadia Howlader, MS, PhD1; S. Jane Henley, MSPH4; Robert N. Anderson, PhD5;
Albert U. Firth, BS2; Jiemin Ma, PhD, MHS6; Betsy A. Kohler, MPH, CTR3; and Ahmedin Jemal, DVM, PhD 6
BACKGROUND: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates
on cancer occurrence and trends in the United States. METHODS: Incidence data were obtained from the CDC-funded and NCI-
funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the
National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all can-
cers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the
annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rec-
tum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. RESULTS: Overall cancer incidence rates from 2008 to
2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015
decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-
year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18
most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14
of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal
(men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and
women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men
only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial
and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other
racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men
and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from
2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV)
for colorectal cancer, from 55.
This document discusses racial disparities in the treatment of cardiovascular disease. It provides an overview of health care disparities, noting they are differences in quality of care that are not due to access, clinical needs, or patient preferences. The document reviews literature finding racial minorities receive fewer cardiovascular procedures than whites. It also outlines federal programs and recommendations from the Institute of Medicine to address disparities through increased data collection, provider training, and health system changes. The role of perfusionists in efforts to eliminate disparities through education and data collection is discussed.
Why was screening implemented?
What is overdiagnosis?
The evidence for overdiagnosis
Available data
Facts from recent studies
Risks of screening
The illusion of early detection
Harms due to overdiagnosis
Benefit-risk balance
So, what to do?
About mammograms: https://desdaughter.wordpress.com/tag/mammograms/
About overdiagnosis: https://desdaughter.wordpress.com/tag/overdiagnosis/
About screening: https://desdaughter.wordpress.com/tag/screening/
Screening for breast cancer? A decision that belongs to every woman- Informat...Cancer Rose
Brochure for women information on breast cancer screening.
Cancer Rose is a French non-profit organization of health professionals.
Independent French medical doctors and a doctor in toxicology, have created the site www.cancer-rose.fr to inform you of the most recent and relevant data on breast cancer mass screening.
By decoding and popularizing the most recent research findings published in the most important international medical journals, analyzing the controversy and providing a social and feminine analysis, our objective is to inform women concerned by breast cancer mass screening in order to help them making their choice and to provide independent information resources to interested physicians.
Cancer Rose has no sponsorships, honoraria, monetary support or conflict of interest from any commercial sources.
Breast cancer is a disease that forms from cancerous cells in the breast, most commonly found in the lobules. Around 12% of women will develop invasive breast cancer in their lifetime. Risk factors include family history, reproductive history, alcohol consumption, old age, race/ethnicity, and diet and exercise. Mutated BRCA1 and BRCA2 genes can also play a role in breast cancer development. Symptoms may include breast lumps, nipple discharge, skin changes, and breast shape changes. Treatment options include surgery such as lumpectomy or mastectomy, chemotherapy, and radiotherapy. Breast cancer remains a leading cause of cancer death in women.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Similar to Reducing Cancer Challenge Webinar Slides (12/6/12) (20)
The Catalyst @ Health 2.0/Wipfli Survey on the State of Digital Health 2021 -...health2dev
The final results are in! Take a look now to see the output of the analysis on the Catalyst @ Health 2.0/Wipfli Survey on the State of Digital Health - 2021!
The 2018 AMR API study from Health 2.0. A survey of the experience of the small health tech application companies working with the large EMR vendors. This is an update and expansion of a similar 2016 study. Both studies supported by the California Health Care Foundation.
Every quarter, Health 2.0 releases a summary set of data that explains where industry funding is going, which product segments are growing fastest, and where new company formation is happening. Health 2.0’s precision and clarity when it comes to market segmentation and product information make this quarterly release the cream of the freebie crop.
Every quarter, Health 2.0 releases a summary set of data that explains where industry funding is going, which product segments are growing fastest, and where new company formation is happening. Health 2.0’s precision and clarity when it comes to market segmentation and product information make this quarterly release the cream of the freebie crop.
Anatomy of a Pilot at Health 2.0 Provider Symposium - Canopy Appshealth2dev
The document discusses the benefits of meditation for reducing stress and anxiety. Regular meditation practice can help calm the mind and body by lowering heart rate and blood pressure. Studies have shown that meditating for just 10-20 minutes per day can have significant positive impacts on both mental and physical health over time.
Anatomy of a Pilot at Health 2.0 Provider Symposium - Optimahealth2dev
This document discusses the costs associated with uncontrolled hypertension, including costs of avoidable emergency department visits and hospitalizations. It then presents a medication optimization workflow powered by artificial intelligence to generate treatment recommendations. The workflow assesses blood pressure control, generates optimized treatment plans, and provides decision support to clinicians via electronic health records. Initial outcomes from piloting this system showed improved blood pressure control and lessons around interoperability, care coordination, and clinical efficacy. Next steps involve piloting the system more broadly and developing similar tools for other conditions.
Anatomy of a Pilot at Health 2.0 Provider Symposium - Clinical Box and Lowell...health2dev
The document summarizes key points from a health 2.0 provider symposium discussing managing patient care across transitions, challenges with procedure cancellations, and the need for changes to care coordination and patient engagement due to payment reform pressures. It then provides details on a pilot program using a clinical coordination platform to activate patients, engage families, identify high-risk patients, coordinate providers, and measure costs and quality. The pilot saw improvements in efficiency and outcomes. Lessons learned focused on starting small, demonstrating value to key stakeholders, ensuring business model alignment, and persevering through challenges in the healthcare industry.
Anatomy of a Pilot at Health 2.0 Provider Symposium - Refer Well and Mount Si...health2dev
Mount Sinai Health System implemented a pilot program with ReferWell to streamline their referral process. The pilot aimed to integrate ReferWell's technology with Mount Sinai's Epic and IDX electronic medical record (EMR) systems to manage referrals. Over the 6-month pilot period, ReferWell supported 24,000 referrals across 125 users and 50+ locations. The pilot showed a 50-92% increase in completed patient visits. Based on the pilot's success, Mount Sinai planned to fully integrate ReferWell with their scheduling systems. The presentation provided tips for successful vendor pilots, including thorough planning, clear metrics, effective communication, and consideration of the post-pilot period.
Aneesh Chopra's Keynote at the Health 2.0's Provider Symposiumhealth2dev
This document discusses the importance of open standards and APIs in healthcare to enable data sharing and the development of consumer applications. It provides examples of initiatives promoting open standards for smart grids, solar energy adoption, and health data exchange. The document advocates that regulations should require certified EHRs to provide consistent, standards-based access to data via open APIs in order to encourage an open healthcare ecosystem with diverse applications. It also highlights testing frameworks that can validate open API conformance and functionality.
With support from California Health Care Foundation, earlier this year (2016) Health 2.0 surveyed over 100 small health tech companies to ask their experiences integrating with specific EMR vendors.
Every quarter, Health 2.0 releases a summary set of data that explains where industry funding is going, which product segments are growing fastest, and where new company formation is happening. Health 2.0’s precision and clarity when it comes to market segmentation and product information make this quarterly release the cream of the freebie crop.
This document summarizes a webinar on launching products in India. It introduces representatives from Becton Dickinson India and Apollo Hospitals who discuss their perspectives on distribution and working with hospitals. Key challenges of the Indian market include its large size and fragmentation requiring multi-tier distribution networks. Success requires understanding customer needs, having the right KPIs, building relationships with distributors, and commitment to adapting to the local market. The hospital perspective emphasizes landscape research, solving clear problems, considering alternatives, and adapting to the market.
Mu3 dev challenge project plan for health 2.0 launch (1)health2dev
This document provides information about the Allscripts Open MU3 Stage 3 API Patient Engagement Challenge. The challenge aims to identify applications that can help hospitals and providers meet the Meaningful Use Stage 3 requirement for patients to access their health information via API from the electronic health record. To be considered, applications must connect to three Allscripts EHRs, engage patients in an easy-to-use way, and allow access to health data in standard formats. Submissions will be evaluated on criteria like usability, API integration, and potential for widespread adoption to improve patient engagement. The timeline outlines key dates for the challenge process.
TechEmerge Webinar, Understanding the Basics: HealthTech in Indiahealth2dev
This document provides an overview of the healthcare industry in India through presentations from various experts. It discusses that while insurance penetration and health statistics are currently low in India, there are significant opportunities for innovation to address problems. The healthcare industry is large and growing, with increasing private sector investment and expansion into rural areas. Major trends include a shift to non-communicable diseases, emerging telemedicine, and growing private equity interest. The document breaks down spending on various healthcare segments and technologies such as hospitals, diagnostics, medical devices, and healthcare IT. It also outlines challenges foreign companies face in understanding and entering the Indian market successfully.
Every quarter, Health 2.0 releases a summary set of data that explains where industry funding is going, which product segments are growing fastest, and where new company formation is happening. Health 2.0’s precision and clarity when it comes to market segmentation and product information make this quarterly release the cream of the freebie crop.
FoodCare helps food and beverage businesses understand and meet the needs of millions of individuals and families by providing nutrition-related apps and services.
Reducing Cancer Challenge Webinar Slides (12/6/12)
1. On
the
Call:
Dr.
David
Hunt,
Medical
Officer
-‐
ONC
Dr.
Paris
Butler,
Clinical
Advisory
to
the
Deputy
Assistant
Secretary
for
Minority
Health
Hemali
Thakkar,
Challenger
Manager
–
Health
2.0
Today’s
Agenda:
Introduc,ons
Brief
Challenge
Overview
Q&A
Office
of
the
Na,onal
Coordinator
for
1
Health
Informa,on
Technology
2. ONC
and
I2
Goals
• Better Health, Better Care, Better Value through Quality Improvement
• Further the mission of the Department of Health and Human Services
• Highlight programs, activities, and issues of concern
• Spur Innovation and Highlight Excellence
• Motivate, inspire, and lead
• Community building – Development of ecosystem
• Stimulate private sector investment
Office
of
the
Na,onal
Coordinator
for
2
Health
Informa,on
Technology
3. Over
300,000
new
breast
and
gynecologic
cancers
are
diagnosed
each
year
with
68,000
deaths
annually.
Office
of
the
Na,onal
Coordinator
for
3
Health
Informa,on
Technology
4. Breast
Cancer
hZp://www.cdc.gov/cancer/breast/
In
the
United
States
in
2008,*
210,203
women
were
diagnosed
with
breast
cancer,
and
40,589
women
died
from
the
disease.†
Except
for
skin
cancer,
breast
cancer
is
the
most
common
cancer
among
American
women.
*Latest
year
for
which
sta,s,cs
are
available.
†Source:
USCS.
Office
of
the
Na,onal
Coordinator
for
4
Health
Informa,on
Technology
5. Gynecologic
Cancers
Each
gynecologic
cancer
is
unique,
with
different
signs,
symptoms,
risk
factors
(things
that
may
increase
your
chance
of
geBng
a
disease),
and
prevenDon
strategies.
Every
year,
more
than
80,000
women
in
the
U.S.
are
told
they
have
a
gynecologic
cancer,
and
more
than
25,000
women
die
from
a
gynecologic
cancer.*
*Source:
U.S.
Cancer
Sta0s0cs
Working
Group
Office
of
the
Na,onal
Coordinator
for
5
Health
Informa,on
Technology
6. Age-‐Adjusted
Cancer
Incidence
and
Death
Rates:
Female
Breast
and
Gynecologic
by
and
Race
and
Ethnicity,
United
States
Asian/Pacific American Indian/
All Races White Black Islander Alaska Native Hispanic
Female Breast Cancer
Incidence 121.9 122.6 118 87.9 65.6 92.8
Female Breast Cancer Death
Rates 22.5 21.9 31.2 11.9 12.8 14.6
Female Gynecologic
Cancer Incidence 48.4 48.9 45.5 34.4 31.3 45.8
Female Gynecologic Cancer
Death Rates 15.5 15.3 18.9 10.3 11.9 12.6
Rates
are
per
100,000
persons
and
are
age-‐adjusted
to
the
2000
U.S.
standard
popula,on
(19
age
groups-‐Census
P25-‐1130).
hZp://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx
Office
of
the
Na,onal
Coordinator
for
6
Health
Informa,on
Technology
7. *Rates
are
per
100,000
persons
and
are
age-‐adjusted
to
the
2000
U.S.
standard
populaDon
(19
age
groups-‐Census
P25-‐1130).
140
120
Female
Breast
Incidence
Female
Genital
System
Incidence
100
80
60
40
20
0
All
Races
White
Black
Asian/Pacific
Islander
American
Indian/Alaska
Hispanic
Office
of
the
Na,onal
Coordinator
for
Na,ve
7
Health
Informa,on
Technology
8. *Rates
are
per
100,000
persons
and
are
age-‐adjusted
to
the
2000
U.S.
standard
populaDon
(19
age
groups-‐Census
P25-‐1130).
35
30
Female
Breast
Death
Rates
25
Female
Genital
Death
Rates
20
15
10
5
0
All
Races
White
Office
Black
Na,onal
Asian/Pacific
Islander
American
Indian/Alaska
Na,ve
of
the
Coordinator
for
Hispanic
8
Health
Informa,on
Technology
9. While
the
incidence
and
prevalence
of
these
cancers
are
widespread
as
depicted
by
this
data,
dispari,es
in
preven,on,
early
treatment,
quality
of
care,
and
outcomes
result
in
higher
morbidity
and
mortality
rates
among
minority
and
underserved
women.
Office
of
the
Na,onal
Coordinator
for
9
Health
Informa,on
Technology
10. The
Challenge
• The
Challenge
calls
on
sohware
developers
to
create
an
applica,on
for
mobile
devices,
in
mul,ple
languages,
that
can
help
underserved
and
minority
women
fight
and
prevent
cancer.
• Providing
general
informa,on
regarding
preven,ve
and
screening
services
for
breast
and
gynecologic
cancers—including,
but
not
limited
to,
benefits,
,ming,
scheduling,
and
loca,on.
• Allowing
for
the
interface
with
pa,ent
health
records
or
provider-‐
sponsored
pa,ent
portals
to
provide
specific
reminders
and
trigger
electronic
health
record-‐based
clinical
decision
support
regarding
the
,ming
of
preven,ve
services.
Office
of
the
Na,onal
Coordinator
for
10
Health
Informa,on
Technology
11. The
Challenge
(cont’d)
• Suppor,ng
the
storage,
viewing,
and
even
the
exchange
of
complex
pa,ent
care
plans.
In
par,cular,
the
applica,on
will
help
strengthen
communica,on
among
provider
care
teams,
possibly
spread
out
across
large
geographic
loca,ons,
to
afford
op,mal
remote
follow-‐up
(e.g.
be
able
to
send
pa,ent
informa,on
to
electronic
health
records
via
Direct,
hZp://directproject.org/).
• Suppor,ng
pa,ent
engagement
and
care
giver
support
with
applica,ons
that
help
pa,ents
and/or
their
caregivers
keep
track
of
complex
care
plans,
such
as
connec,ons
to
community
health
workers,
promotores
de
salud,
or
pa,ent
navigators.
Office
of
the
Na,onal
Coordinator
for
11
Health
Informa,on
Technology
12. Judging
Criteria
• PaDent
engagement:
Incorpora,ng
pa,ent-‐reported
informa,on
• Quality
and
accessibility
of
informaDon:
Providing
high
quality,
evidence-‐based
informa,on
and
interven,ons
using
plain
language,
a
clear
display
that
considers
usability
on
a
small-‐screen
interface
(Web
Usability
and
Aging,
Usability
and
Mobile
Devices),
and
targe,ng
pa,ents
with
a
range
of
health
literacy
levels
• Targeted
and
acDonable
informaDon:
Providing
tailored
informa,on,
recommenda,ons,
and
reminders
• Links
to
online
communiDes
and/or
social
media:
Link
pa,ents
with
others
who
are
facing
the
same
health
challenges
through
social
media
sites
or
organiza,ons,
such
as
the
American
Cancer
Society,
and
to
other
sources
of
support,
such
as
community
health
workers,
pa,ent
navigators,
or
promotores
de
salud
• InnovaDveness
and
usability:
Innova,veness
and
an
easy-‐to-‐use
interface
for
pa,ents
with
a
range
of
experiences
and
comfort
levels
with
technology
• Non-‐English
language
availability:
Availability
of
the
tool
in
languages
used
in
minority
and
underserved
communi,es
Office
of
the
Na,onal
Coordinator
for
12
Health
Informa,on
Technology
13. Timeline
Submission
Period
Begins:
August
23,
2012
Submission
Period
for
Entries
Ends:
February
5,
2013
Evalua,on
Process
for
Entries
Begins:
February
8,
2013
Evalua,on
Process
for
Entries
Ends:
February
19,
2013
Winners
no,fied:
February
24,
2013
Winners
Announced:
Conference
TBD,
March-‐April
2013
Office
of
the
Na,onal
Coordinator
for
13
Health
Informa,on
Technology
14. Prizes
First
Place:
$85,000
+
demo
opp
at
conf
Second
Place:
$10,000
Third
Place:
$5,000
Not
to
men?on:
recogni?on,
publicity,
credibility
and
reach!
Office
of
the
Na,onal
Coordinator
for
14
Health
Informa,on
Technology
15. Ques,ons?
www.health2challenge.org
Contact Hemali:
hemali@health2con.com
Office
of
the
Na,onal
Coordinator
for
15
Health
Informa,on
Technology